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Repeat course of rabbit antithymocyte globulin as
salvage following initial therapy with rabbit 
antithymocyte globulin in acquired aplastic anemia
The treatment for the majority of patients with
acquired aplastic anemia (AA) who are not suitable for
hematopoietic stem cell transplant (HSCT) is immuno-
suppression with standard horse antithymocyte globulin
(h-ATG) and cyclosporine (CSA) where hematologic
responses are observed in 60-70%.1However, since 2007,
h-ATG is no longer available in most Latin American,
Asian and European countries, with rabbit ATG (r-ATG)
being the only accessible formulation.2,3 Hematologic
response and overall survival when using r-ATG as first-
line therapy for AA are significantly inferior as compared
to h-ATG.1,3,4 This led to many patients having need of
salvage therapies following initial r-ATG. A repeat course
of immunosuppression with h-ATG or alemtuzumab in
this setting of initial r-ATG failure yields a response rate
of about 20%,5,6 but the outcomes of repeating a course
with the same formulation of r-ATG in this scenario are
not known. 
To address this question, we conducted a retrospective
analysis of 39 patients diagnosed with AA who failed or
relapsed after initial r-ATG/CsA and were retreated with
r-ATG/CsA as salvage between January 2005 and January
2014 at two marrow failure centers in Brazil (University
of São Paulo at Ribeirão Preto School of Medicine,
Ribeirão Preto, SP and Hemorio, Rio de Janeiro, RJ) and
one in Argentina (Hospital Juan P. Garrahan, Buenos
Aires). The respective local institution review boards
approved the study.
Aplastic anemia was diagnosed and disease severity
classified according to established criteria7,8 (for details
see Online Supplementary Methods). Response to immuno-
suppression was assessed at three and six months follow-
ing the commencement of therapy.  For patients with
severe AA (SAA) and very severe AA (vSAA), response
was defined as no longer meeting severity criteria and
achieving transfusion independence for 1 month or
longer. For non-severe AA (NSAA) patients, response
was defined as transfusion independence for 1 month or
longer. A patient was considered refractory when they
did not fulfill response criteria. Relapse was considered if
the patient had a previous response following r-ATG/CsA
and once more became transfusion dependent or met cri-
teria for SAA or vSAA. For patients with NSAA, only
transfusion-dependent patients were retreated. Of the 39
AA patients, 34 received salvage r-ATG/CsA according to
respective institutional protocols in the three centers. The
remaining five patients were enrolled in one of the insti-
tutions in a single-arm phase II study of salvage r-
ATG/CsA associated with 2-5 weekly intravenous infu-
sions of allogeneic marrow derived mesenchymal stromal
cells (NCT01297972). This intervention was found not to
alter immunosuppression response, thus their data were
combined for the purpose of analysis. Patients with con-
stitutional AA or who did not complete the five-day r-
ATG schedule were excluded from analysis. All patients
received r-ATG (Thymoglobulin®, Genzyme Corporation,
Cambridge, MA, USA) at variable doses (median, 3.5
mg/kg/d; range, 1.65-5.0), for five consecutive days,
depending on individual institutional protocols (see
Online Supplementary Methods). CsA was started on day 1
at 5 mg/kg/d in two divided doses, and adjusted to main-
tain a serum trough level of 150–400 ng/ml for at least six
months. For survival analysis, the Kaplan–Meier esti-
mates were based on the survival days from the start of
the salvage r-ATG therapy, and patients were censored at
the time of last visit, death or HSCT. Differences in
response rates between AA severity groups were evaluat-
ed by Fisher’s exact test. Comparison of overall survival
(OS) between responders and non-responders was per-
formed by the log-rank test.
Thirty-nine patients received retreatment with r-
ATG/CsA; two received r-ATG for only one day  due to
severe allergic reaction and were thus excluded from this
analysis. Data from the remaining 37 patients are pre-
sented. After a median of 283 days from first r-ATG/CsA
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Table 1. Patients' characteristics.
Characteristic                                                                   N=37
Age – years, median (range)                                                    17 (3-63)
Male – no. (%)                                                                               21 (57)
Disease severity – no. (%)                                                                
Non-severe                                                                                      4 (11)
Severe                                                                                              20 (54)
Very severe                                                                                     13 (35)
Absolute neutrophil count – x109/L, median (range)      0.45 (0-1.74)
GPI-negative clone – no. (%)*                                                         
<1%                                                                                                   30 (81)
≥1%                                                                                                     2 (5)
Type of response to first rATG – no. (%)                                      
Refractory                                                                                       32 (86)
Relapse                                                                                             5 (14)
First rATG dose – mg/kg/day x 5 days,                                          3.1 
median (range)                                                                            (1.5-5.0)
Second rATG dose – mg/kg/day x 5 days,                                     3.5 
median (range)                                                                            (1.7-5.0)
Time from first rATG to second rATG – days,                           283 
median (range)                                                                          (118-2379)
*Not performed in 5 cases. GPI: glycosylphosphatidylinositol; rATG: rabbit antithymo-
cyte globulin. 
Table 2. Hematologic response at 3 and 6 months to second course rabbit ATG plus cyclosporine.
Refractory to first 95% CI Relapsed to first 95% CI
r-ATG/CsA r-ATG/CsA
(n=32) (n=5)
Response at 3 months 5 (16%) 3-28% 3 (60%) 17-100%
no. (%)
Response at 6 months 7 (22%) 8-36% 3 (60%) 17-100%
no. (%)
(range, 118-2379), 37 patients (32 refractory and 5
relapsed) received a second five-day r-ATG course fol-
lowed by CsA. Table 1 summarizes patients’ characteris-
tics. After a median follow-up of 24 months (range, 0.2-
77), hematologic response was observed in 8 (22%)
patients at 3 months and in 10 (27%) patients at 6
months for the entire cohort. Among those who were
refractory to initial r-ATG, 7 out of 32 (22%) responded
at 6 months (Table 2). Among those who had previously
relapsed, 3 out of 5 (60%) responded (Table 2). None of
the four patients classified as NSAA at diagnosis respond-
ed to the second r-ATG. Among those with more severe
disease (vSAA or SAA) the hematologic response rate at
6 months was 10/33 (30%), with 7/20 (35%) patients
with SAA and 3/13 (23%) with vSAA responding. Of
these 10 responders, two patients relapsed at days 170
and 897 after retreatment, and were alive at last follow-
up. These latter evolved to myelodysplastic syndrome
(MDS) with normal karyotype. Among all non-respon-
ders (n=27), five clonal evolutions were observed: four to
monosomy 7 and one to trisomies 8 and 21. In the entire
cohort, three patients underwent HSCT due to refractory
disease or evolution to MDS. In total, 12 patients died, all
from among non-responders, and invasive fungal infec-
tion was the most frequent cause of death (3 out of 12).
The overall survival at 4 years was 55% (95% CI, 33-
72%; Figure 1A). Survival was superior in patients who
responded to the second r-ATG/CsA as compared to non-
responders (P=0.004; Figure 1B), and there was no statis-
tical difference in survival for those who were refractory
or relapsed (Figure 1C).
Thus, in the present study, we show that approximate-
ly only one in five AA patients who had not responded to
first-line r-ATG/CsA may be rescued with a second
course of r-ATG/CsA. Among those with SAA or vSAA
(excluding NSAA), this rate was about 30% in our cohort.
The salvage rate with h-ATG/CsA or alemtuzumab in
this setting has been reported to be comparably low: only
8% for alemtuzumab and 21% for h-ATG.5,6 Taking into
account that only one-third of patients respond to initial
r-ATG,1 it is reasonable to assume that at least half of AA
patients will remain refractory to immunosuppression,
even with repeat courses of r-ATG, h-ATG, or alem-
tuzumab when r-ATG is used in first-line therapy. The
high success rate of initial h-ATG therapies cannot be
recapitulated when r-ATG is administered first, given the
low rate of hematologic responses with 1 or 2 courses
after initial r-ATG, reinforcing the necessity for an effec-
tive “first shot” when treating AA with immunosuppres-
sion. With an initial response rate of 60-70% to h-ATG
directly, and a salvage rate of about 30-40% (with repeat
ATG or alemtuzumab), hematologic responses can be
anticipated in 70-85% of cases when ISTs are adminis-
tered in this order.1,4,5,9-12 
We also show that achieving a response to a second
course of r-ATG is strongly associated with excellent
long-term survival.3,9,12 The achievement of hematologic
response has been a consistent and reliable surrogate for
long-term survival in treatment-naïve SAA, and is con-
firmed in our cohort.9,12,13 
In patients who had a previous response to r-ATG/CsA
and relapsed, retreatment with r-ATG/CsA may associate
with better results, with 3/5 (60%) patients responding.
Despite the limited patient number, this result is compa-
rable to that previously reported in the relapsed setting
following h-ATG.5,9 This difference in salvage rates
between refractory and relapsed patients has been con-
sistently shown, and may reflect distinct mechanisms for
marrow failure. Relapsed patients have immunomodula-
tory responsive disease (exhibited with the initial
response) and are probably more amenable to further
immunomodulation. In contrast, refractoriness to first
ATG may reflect alternative or additional mechanisms,
such as severe hematopoietic stem cell depletion or a
non-immune basis. 
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Figure 1. Overall survival curves. (A) Survival for the entire cohort
of aplastic anemia patients who failed or relapsed after initial r-
ATG/CsA and were retreated with r-ATG/CsA (n=37); dotted lines
represent 95% confidence intervals (CI). (B) Survival of patients
who responded (n=10) or did not respond (n=27) at 6 months after
the second course of r-ATG/CsA. (C) Survival after second r-
ATG/CSA of AA patients who were refractory (solid line) or
relapsed (dotted line) after first r-ATG/CSA. Patients who under-
went hematopoietic stem cell transplantation were censored at
the time of transplant.
A
B
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Given the low salvage following r-ATG, other rescue
therapies could be considered that may include alterna-
tive donor HSCT, thrombopoietin receptor agonists, or
alternative experimental therapies. It has recently been
shown that eltrombopag induces hematologic response
in up to 44% of refractory SAA patients, which included
trilineage responses.14 This was expanded to a larger
cohort with longer follow-up which confirmed the
response rate of about 40%, and multilineage increments
in blood counts were again observed.15 One of the con-
cerns related to rescue eltrombopag is the potential
propensity to stimulate clonal evolution. However, the
clonal evolution rate of 19%, as reported in initial eltrom-
bopag studies, is similar both to our current analysis and
to that reported in refractory SAA.5,9,12,14,15 Ongoing studies
employing eltrombopag in combination with h-
ATG/CsA as first therapy will further elucidate the clonal
evolution risk. 
In the aggregate, the high success rate of initial h-ATG
therapies cannot be recapitulated when r-ATG is admin-
istered first, given the relatively low salvage rate with
alemtuzumab, h-ATG and now (current data) with r-ATG.
This observation emphasizes the importance of initiating
immunosuppressive therapy in SAA with h-ATG, which
is associated with better outcomes overall. For those
refractory to initial r-ATG a repeat course of IST can be
effective and produce clinically meaningful hematologic
responses in about 20-30% of cases. It is reasonable to
consider alternative non-IST (transplant and non-trans-
plant) therapies in this patient population. Those who
relapse following initial r-ATG appear to fare better with
a higher response rate. It seems unlikely that a more
definitive prospective study will be conducted to better
define the role of salvage r-ATG following initial r-ATG,
thus leaving retrospective studies such as ours as the
principal guide for hematologists who care for patients
with marrow failure disorders.
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